Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2012

A reconciliation of the numerator and denominator used in the calculation is as follows (in thousands, except per share amounts):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Numerator:
Net loss — basic	$	(991	)	$	(4,125	)	$	(99,523	)	$	(20,378	)
Less: noncash income from change in fair value of common stock warrants		(2,967	)		—			—			—

Net loss — diluted	$	(3,958	)	$	(4,125	)	$	(99,523	)	$	(20,378	)

Denominator:
Weighted average common shares outstanding		55,654			49,052			53,516			44,812
Dilutive effect of warrants		8,751			—			—			—

Weighted-average common shares outstanding and potential dilutive common shares — diluted		64,405			49,052			53,516			44,812

Net loss per share
Basic	$	(0.02	)	$	(0.08	)	$	(1.86	)	$	(0.45	)

Diluted	$	(0.06	)	$	(0.08	)	$	(1.86	)	$	(0.45	)

would have had an antidilutive effect. The amounts disclosed below are prior to the application of the treasury stock method (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Shares issuable upon exercise of warrants		—		16,643		11,726		16,643
Shares issuable upon exercise of stock options		5,129		3,531		5,129		3,531
Shares issuable related to the ESPP		48		40		48		40